SCHEMBL773038

SCHEMBL773038

CCOC(=O)Cc1nc(-c2cc(F)ccc2F)no1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.55
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
TSHR P16473 2/20 0.45
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 2/20 0.39
AKR1B1 P15121 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1704192 0.93 S1PR1 (0.49) S1PR1ALDH1A1LMNATSHRTP53
SCHEMBL775210 0.84 S1PR1 (0.43) S1PR1ALDH1A1LMNATSHRTP53
SCHEMBL1703767 0.82 AKR1B1 (0.50) S1PR1TSHRHTTGAASMN1; SMN2
SCHEMBL774234 0.81 S1PR1 (0.44) S1PR1ALDH1A1LMNATSHRTP53
SCHEMBL771644 0.78 S1PR1 (0.44) S1PR1ALDH1A1LMNATSHRMAPT
SCHEMBL773983 0.78 AKR1B1 (0.47) S1PR1ALDH1A1LMNATSHRTP53
SCHEMBL772932 0.77 S1PR1 (0.44) S1PR1ALDH1A1LMNAMAPTHTT
SCHEMBL4658742 0.74 KCNH2 (0.64) LMNAMAPTSMN1; SMN2KMT2ANPC1
SCHEMBL1543797 0.74 S1PR1 (0.45) S1PR1ALDH1A1TSHRHTTSMN1; SMN2
SCHEMBL772948 0.74 HPGD (0.39) S1PR1LMNATSHRTP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
EP-2440554-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS Merck Serono S.A. (CH) 2012-04-18 EP disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 S1PR1 1/4885ALDH1A1 1615/4885LMNA 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.